These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 33965978)

  • 1. Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis.
    Quhal F; Mori K; Remzi M; Fajkovic H; Shariat SF; Schmidinger M
    Curr Opin Urol; 2021 Jul; 31(4):332-339. PubMed ID: 33965978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Alam MU; Jazayeri SB; Gautam S; Norez D; Kumar J; Tanneru K; Nguyen S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Am J Clin Oncol; 2020 Jul; 43(7):477-483. PubMed ID: 32251121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
    Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
    BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
    Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
    EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
    Tamada S; Kondoh C; Matsubara N; Mizuno R; Kimura G; Anai S; Tomita Y; Oyama M; Masumori N; Kojima T; Matsumoto H; Chen M; Li M; Matsuda K; Tanaka Y; Rini BI; Uemura H
    Int J Clin Oncol; 2022 Jan; 27(1):154-164. PubMed ID: 34800178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Miura N; Karakiewicz PI; Luzzago S; Schmidinger M; Bruchbacher A; Pradere B; Egawa S; Shariat SF
    Cancer Immunol Immunother; 2021 Feb; 70(2):265-273. PubMed ID: 32757054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Bosma NA; Warkentin MT; Gan CL; Karim S; Heng DYC; Brenner DR; Lee-Ying RM
    Eur Urol Open Sci; 2022 Mar; 37():14-26. PubMed ID: 35128482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
    Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
    Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis.
    Fujiwara Y; Miyashita H; Liaw BC
    Cancer Immunol Immunother; 2023 Jun; 72(6):1355-1364. PubMed ID: 36495342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
    Wang S; Lv H; Yu J; Chen M
    Int Immunopharmacol; 2024 Apr; 131():111884. PubMed ID: 38518592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
    Spisarová M; Melichar B; Vitásková D; Študentová H
    Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
    [No Abstract]   [Full Text] [Related]  

  • 16. Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.
    Chau V; Bilusic M
    Cancer Manag Res; 2020; 12():7321-7330. PubMed ID: 32884346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
    Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
    Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
    Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
    J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis.
    Massari F; Mollica V; Rizzo A; Cosmai L; Rizzo M; Porta C
    Expert Opin Drug Saf; 2020 Oct; 19(10):1329-1338. PubMed ID: 32799582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
    Krawczyk K; Śladowska K; Holko P; Kawalec P
    Front Pharmacol; 2023; 14():1223929. PubMed ID: 37745049
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.